|
|
|
|
|
|
| An Update on QUILT-3.032: Complete Responses to N-803 plus BCG Therapy in BCG-Unresponsive Bladder Carcinoma In Situ (CIS) with or without Ta/T1 Papillary Disease
|
| Sam Chang, MD, MBA
|
| Sam Chang presented an update on the QUILT-3.032 trial, showing that the combination of N-803 (ANKTIVA) plus BCG therapy achieved a 71% complete response rate in BCG-unresponsive CIS with or without papillary disease, with a 36-month cystectomy-free survival rate of 84%. The treatment also demonstrated long-term efficacy in BCG-unresponsive papillary-only disease, with a 36-month cystectomy-free survival rate of 82%. N-803 plus BCG was well-tolerated, with minimal adverse events.4o mini
|
|
|
|
|
|
| Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer with UGN-102: Ongoing Results from a Single-Arm, Open-Label, Phase 3 Trial (ENVISION)
|
| Sandip Prasad, MD, MPhil
|
| Sandip Prasad presented interim results from the ENVISION trial, showing that UGN-102 achieved an 80% complete response rate at 3 months in patients with recurrent low-grade, intermediate-risk NMIBC, with 81% maintaining response at 12 months. UGN-102 was generally well-tolerated, offering a promising non-surgical alternative to TURBT for this patient population.
|
|
|
|
|
|
| Performance of Minimal Residual Disease Detection with Urine-Derived DNA in High-Grade Bladder Cancer Patients Undergoing Recommended Repeat Transurethral Resection
|
| John Ogunkeye, MD
|
| During the non-invasive bladder cancer podium session, Dr. John Ogunkeye presented a study evaluating the performance of minimal residual disease detection with urine-derived DNA in high-grade bladder cancer patients undergoing a recommended repeat TURBT.
|
|
|
|
|
|
|
|
|
|
|
| Preliminary Efficacy and Safety of Disitamab Vedotin Combined with BCG in the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer with HER2 Expression: A Prospective, Open Label, Single-Center Study |
| Yijun Shen, MD |
| Yijun Shen presented preliminary results showing that disitamab vedotin combined with BCG achieved 100% clinical complete response rates at 3 and 6 months in high-risk NMIBC patients with HER2 expression. The treatment was associated with manageable side effects, suggesting it may offer a promising bladder-sparing option for patients who are ineligible for or decline radical cystectomy. |
|
|
|
|
|
| An Artificial Intelligence-powered Predictive Biomarker for Response to Intravesical BCG versus Gemcitabine-Docetaxel for High-Grade Non-Muscle Invasive Bladder Cancer |
| Vignesh Packiam, MD |
| Vignesh Packiam presented data showing that an AI-powered histologic biomarker (CHAI) can predict which high-risk NMIBC patients respond better to BCG versus gemcitabine + docetaxel. Patients who were CHAI biomarker-positive had significantly better recurrence-free survival with gemcitabine + docetaxel than with BCG, suggesting this tool could guide more personalized, effective treatment selection. |
|
|
|
|
|
| Bladder EpiCheck-triggered Photodynamic Diagnosis Biopsies Detect High Grade Recurrences Missed by White Light Cystoscopy |
| Paramananthan Mariappan, MBBS, PhD, FRCS(Urol), FEBU, FRCSEd |
| Paramananthan Mariappan presented a study showing that Bladder EpiCheck combined with photodynamic diagnosis (PDD)-guided biopsies detected 44% more high-grade NMIBC recurrences, including CIS, than white light cystoscopy (WLC) alone. Using Bladder EpiCheck for surveillance could reduce 95% of unnecessary cystoscopies while maintaining a 96% detection rate for high-grade disease, offering a more efficient and sensitive approach for bladder cancer monitoring. |
|
|
|
|
|
| Dissecting Genomic Features of BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Identifies Drivers of Sensitivity to Intravesical Gemcitabine/Docetaxel |
| Kendrick Yim, MD |
| Kendrick Yim presented genomic profiling data showing that BCG-unresponsive NMIBC tumors with CREBBP, STAG2, and clonal BAP1 mutations may be more sensitive to intravesical gemcitabine + docetaxel. Identifying these mutations could help predict which patients will achieve long-term responses to chemotherapy, offering a path toward more personalized treatment strategies. |
|
|
|
|
|
|
|
|
|
|
